This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CTI BioPharma Crecimiento futuro

Future controles de criterios 5/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for CTI BioPharma.

Información clave

60.0%

Tasa de crecimiento de los beneficios

61.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	32.0%
Tasa de crecimiento de los ingresos	34.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	27 Jun 2023

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:CEPS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	309	99	N/A	N/A	4
12/31/2024	221	36	N/A	N/A	6
12/31/2023	117	-39	N/A	N/A	4
3/31/2023	76	-69	-82	-82	N/A
12/31/2022	54	-93	-81	-81	N/A
9/30/2022	33	-112	-96	-96	N/A
6/30/2022	15	-121	-101	-101	N/A
3/31/2022	2	-118	-98	-98	N/A
12/31/2021	N/A	-98	-85	-85	N/A
9/30/2021	N/A	-76	-66	-66	N/A
6/30/2021	N/A	-63	-57	-57	N/A
3/31/2021	N/A	-58	-49	-49	N/A
12/31/2020	N/A	-52	-42	-42	N/A
9/30/2020	N/A	-46	-43	-43	N/A
6/30/2020	2	-44	-37	-37	N/A
3/31/2020	3	-41	-35	-35	N/A
12/31/2019	3	-40	-28	-28	N/A
9/30/2019	17	-31	-29	-29	N/A
6/30/2019	16	-36	-35	-35	N/A
3/31/2019	16	-36	-41	-41	N/A
12/31/2018	26	-29	-40	-40	N/A
9/30/2018	13	-45	-38	-38	N/A
6/30/2018	14	-42	-46	-46	N/A
3/31/2018	35	-29	-33	-33	N/A
12/31/2017	25	-45	-39	-39	N/A
9/30/2017	34	-37	-43	-43	N/A
6/30/2017	37	-54	-36	-36	N/A
3/31/2017	22	-75	-62	-62	N/A
12/31/2016	57	-52	N/A	-77	N/A
9/30/2016	60	-74	N/A	-84	N/A
6/30/2016	56	-78	N/A	-95	N/A
3/31/2016	50	-91	N/A	-94	N/A
12/31/2015	16	-123	N/A	-95	N/A
9/30/2015	23	-138	N/A	-69	N/A
6/30/2015	61	-101	N/A	-50	N/A
3/31/2015	61	-96	N/A	-43	N/A
12/31/2014	60	-96	N/A	-40	N/A
9/30/2014	75	-42	N/A	-33	N/A
6/30/2014	36	-69	N/A	-44	N/A
3/31/2014	35	-59	N/A	-41	N/A
12/31/2013	35	-50	N/A	-36	N/A
9/30/2013	2	-79	N/A	-63	N/A
6/30/2013	1	-77	N/A	-60	N/A
3/31/2013	1	-117	N/A	-59	N/A
12/31/2012	N/A	-115	N/A	-63	N/A
9/30/2012	N/A	-114	N/A	-51	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: CEPS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Beneficios vs. Mercado: CEPS is forecast to become profitable over the next 3 years, which is considered above average market growth.

Beneficios de alto crecimiento: CEPS is expected to become profitable in the next 3 years.

Ingresos vs. Mercado: CEPS's revenue (34% per year) is forecast to grow faster than the German market (3.5% per year).

Ingresos de alto crecimiento: CEPS's revenue (34% per year) is forecast to grow faster than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if CEPS's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

CTI BioPharma Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from NASDAQ Composite Index

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P TMI Index

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Comp Value Index

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

CTI BioPharma Corp. to Report Q3, 2022 Results on Nov 07, 2022

CTI BioPharma Corp. Announces Executive Changes

CTI BioPharma Corp. Announces Presentation of New Anemia Benefit Data from Pacritinib Program At the Society of Hematologic Oncology Tenth Annual Meeting

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. to Report Q2, 2022 Results on Aug 08, 2022

CTI BioPharma Corp., Annual General Meeting, Jun 01, 2022

National Comprehensive Cancer Network Recommends CTI BioPharma Corp.'s VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. appoints James K. Fong as senior vice president and chief commercial officer

CTI BioPharma Corp. Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

CTI BioPharma Corp. Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis with Severe Thrombocytopenia

CTI BioPharma Corp. Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. to Report Q4, 2020 Results on Mar 17, 2021

Cti Biopharma Corp. Announces Publication of Article Highlighting Pacritinib Data from the Pac203 Phase 2 Study in Myelofibrosis in Blood Advances

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. to Report Q3, 2020 Results on Nov 10, 2020

CTI BioPharma Corp. Initiates Rolling Submission of New Drug Application for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma Corp. Contemplates Bankruptcy

Earnings released

New 90-day high - €1.27

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento